Jupiter Neurosciences CEO And President Talk About The Power of JOTROL And The Launch of Its Longevity Consumer Line With BenzingaDETROIT, MICHIGAN - August 21, 2025 ( NEWMEDIAWIRE ) - Christer Rosen, Chairman and CEO, and Alison Silva, President and CBO at Jupiter Neurosciences Inc . (
NASDAQ: JUNS), sat down with Benzinga to discuss how the company is addressing longevity and brain health with JOTROL™ and its new direct-to-consumer product line, Nugevia.
Jupiter Neurosciences CEO And President Talk About The Power of JOTROL And The Launch of Its Longevity Consumer Line With BenzingaSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Longevity In A Capsule: Jupiter Neurosciences Launches First Three Supplements Under Nugevia(TM) BrandSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Longevity In A Capsule: Jupiter Neurosciences Launches First Three Supplements Under Nugevia(TM) BrandDETROIT, MICHIGAN - August 19, 2025 ( NEWMEDIAWIRE ) - Jupiter Neurosciences Inc . (
NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™ – an enhanced orally administered resveratrol formulation known for its antioxidant and anti-inflammatory effects – is solidifying its two-pronged business approach with the launch of Nugevia™, its direct-to-consumer longevity product line.
From Fighting Inflammation To Regenerating Cells: How Jupiter Neurosciences Is Putting The Pep Back In Our Step As We AgeSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
From Fighting Inflammation To Regenerating Cells: How Jupiter Neurosciences Is Putting The Pep Back In Our Step As We AgeDETROIT, MICHIGAN - July 10, 2025 ( NEWMEDIAWIRE ) - Christer Rosen, chairman & CEO of Jupiter Neurosciences Inc. (
NASDAQ: JUNS), was recently a guest on Benzinga’s All-Access.
How Jupiter Neuroscience's Two-Prong Approach Could Crack The Code On Biotech SuccessSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
How Jupiter Neuroscience's Two-Prong Approach Could Crack The Code On Biotech SuccessDETROIT, MICHIGAN - June 16, 2025 ( NEWMEDIAWIRE ) - While being a biotech company can be difficult, it is not impossible. Just look at Jupiter Neurosciences Inc. (
NASDAQ: JUNS), a clinical-stage pharmaceutical company, for evidence. The company, which is developing drugs to treat neuroinflammation, with a current focus on central nervous system or CNS disorders such as Alzheimer's and Parkinson's and rare diseases, is taking a two-prong approach. That enables it to help people long-term and generate recurring revenue in the short-term.
Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVORLANDO, FL / ACCESS Newswire / March 7, 2025 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Jupiter Neurosciences, Inc. (Nasdaq:JUNS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, March 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
